NON-CONFIDENTIAL

Building Japan’s Next Commercial Biotech
41st Annual J.P. Morgan Healthcare Conference
January 2023 | Sosei Group Corporation (TSE:4565)

Disclaimer
The material that follows is a presentation of general background information about Sosei Group Corporation and its subsidiaries (collectively, the “Company”) as of the date of this presentation. This material has been
prepared solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities and should not be treated as giving investment advice to recipients. It is not targeted to the specificinvestment objectives, financial situation or particular needs of any recipient. It is not intended to provide the basis for any third party evaluation of any securities or any offering of them and should not be considered as arecommendation that any recipient should subscribe for or purchase any securities.
The information contained herein is in summary form and does not purport to be complete. Certain information has been obtained from public sources. No representation or warranty, either express or implied, by theCompany is made as to the accuracy, fairness, or completeness of the information presented herein and no reliance should be placed on the accuracy, fairness, or completeness of such information. The Company takes noresponsibility or liability to update the contents of this presentation in the light of new information and/or future events. In addition, the Company may alter, modify or otherwise change in any manner the contents of thispresentation, in its own discretion without the obligation to notify any person of such revision or changes.
This presentation contains “forward-looking statements,” as that term is defined in Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. The
words “believe”, “expect”, “anticipate”, “intend”, “plan”, “seeks”, “estimates”, “will” and “may” and similar expressions identify forward looking statements. All statements other than statements of historical facts included inthis presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our
products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to bematerially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding ourpresent and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in theforward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment,
unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, thecompetitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, ourrelationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. These factors include, without limitation, those discussed in our public reports filedwith the Tokyo Stock Exchange and the Financial Services Agency of Japan. Although the Company believes that the expectations and assumptions reflected in the forward-looking statements are reasonably based on
information currently available to the Company's management, certain forward looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in thisdocument speak only as at the date of this presentation and the company does not assume any obligations to update or revise any of these forward statements, even if new information becomes available in the future.
This presentation does not constitute an offer, or invitation, or solicitation of an offer, to subscribe for or purchase any securities. Neither this presentation nor anything contained herein shall form the basis of any contract orcommitment whatsoever. Recipients of this presentation are not to construe the contents of this summary as legal, tax or investment advice and recipients should consult their own advisors in this regard.
This presentation and its contents are proprietary confidential information and may not be reproduced, published or otherwise disseminated in whole or in part without the Company’s prior written consent. These materials
are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.
This presentation contains non-GAAP financial measures. The non‐GAAP financial measures contained in this presentation are not measures of financial performance calculated in accordance with IFRS and should not be
considered as replacements or alternatives profit, or operating profit, as an indicator of operating performance or as replacements or alternatives to cash flow provided by operating activities or as a measure of liquidity (ineach case, as determined in accordance with IFRS). Non-GAAP financial measures should be viewed in addition to, and not as a substitute for, analysis of the Company's results reported in accordance with IFRS.
References to "FY" in this presentation for periods prior to 1 January 2018 are to the 12-month periods commencing in each case on April 1 of the year indicated and ending on March 31 of the following year, and the 9 month
period from April 1 2017 to December 31 2017. From January 1 2018 the Company changed its fiscal year to the 12-month period commencing in each case on January 1. References to "FY" in this presentation should beconstrued accordingly.
© Sosei Group Corporation. Sosei Heptares is the corporate brand and trademark of Sosei Group Corporation. Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.

2

From humble beginnings…
1990s

1990 - Founded bycurrent Chairman,
Shinichi Tamura
1992 - ¥100m
Series A financing
1994 - ¥400m
Series B financing

3

2005

2004

IPO on Tokyo Stock
Exchange Mothers(TSE:4565), raisingover ¥11bn

TODAY

2015
Acquisition of
Arakis, adding
respiratory assets
out-licensed to
Novartis andlaunched in 2012

Acquisition of
Heptares Therapeutics,
adding a highly
productive drug
discovery platform

40+ programs
across multiple
therapeutic areas
20+ partnerships
with world leading
pharma companies
and emerging tech
disruptors

…to one of Japan’s most innovative science-led biotech businesses
EVOLVING WITH A SPECIALISTTHERAPEUTIC FOCUS

Proprietary StaR® membraneprotein stabilization technology

Advancing a broad and deep
pipeline of 40 partnered andin-house programs acrossmultiple therapeutic areas:

Structure-based drug discovery
platform, translational medicine
and early clinical development
capabilities in the UK

Neurology
Immunology
Gastroenterology
Other

Japanese clinical development
expertise
Listed on Tokyo Stock Exchange(4565-JP) with ~$500m cash

10%
35%
28%

200+

EMPLOYEESWORLDWIDE

20+WORLD-LEADINGPARTNERS$950M+PARTNER REV.
RECEIVED TO DATE1500+

GLOBALPATENTS

1 Includes upfront and milestone payments, royalties and R&D funding received from active, inactive and completed partnerships from 2005 to 2022.

4

25+

PRECLINICALCANDIDATES

27%

Diversification of a big pharma, catalyst rich upside of a biotech
SELECTED PARTNEREDDISCOVERY
10+ PROGRAMSPRECLINICAL AND PHASE 1

PHASE 2

2x programs

GLP-1 Ag

2x programs

M4 Ag




1x program
1x program

SELECTED IN-HOUSE

EP4 Ant
10+ PROGRAMSGPR52 Ag
EP4 Ag+ Multiple others

 To be discussed today

As a result of our strong focus on alliances, we have received $950+ million to date1
and are eligible to receive $5.6+ billion total payments in the future2
1 Includes upfront and milestone payments, royalties and R&D funding received from active, inactive and completed partnerships from 2005 to 2022.
2 Includes development and commercial milestone payments from active partnerships as of 1 January 2023. Excludes royalties and R&D funding.

5A differentiated business model that delivers
2022 MILESTONESLTM RELATIVE SHARE PRICE PERFORMANCE1

New collaboration with Cancer Research UK
for cancer immunotherapy

New multi-target collaboration with AbbVie
for neurology diseases



M4 Ag Phase 2 IND acceptance by Neurocrine
Biosciences for schizophrenia-7.7%-26.2%
Sosei Group Corporation
Tokyo Stock Exchange Mothers
NASDAQ / Biotechnology

Jan ’22

New multi-target collaboration with Lilly fordiabetes and metabolic diseases

Mar

GLP-1 Agonist Phase 2 clinical trial start by
Pfizer for type 2 diabetes and obesity

Source: 1 FactSet as of 6 January 2023

6

May

Jul

OPERATING CASH FLOW (JPY BILLION)
3.4



+15.1%

2019

Sep

Nov

7.1

4.7

2020

2021

Jan ’23

Clear strategy to drive the business forward
DRUG DISCOVERY
1

TRANSLATIONAL MED.

LATE STAGE CLINICALCOMMERCIAL

3

UK
WORLD-LEADINGDRUG DISCOVERYJapan

TRANSFORMING
IN-HOUSE R&D

4









ACTIVATING JAPAN COMMERCIAL BUSINESSU.S. & E.U.
Partners

2

MAJOR MILESTONE / CASH FLOW GENERATING PARTNERSHIPSWorld-leading science. Life changing medicines

7

DISCOVERY PLATFORM

PARTNERSHIPS

TRANSFORMING R&D

ACTIVATING JAPANWhy GPCRs? The ‘second golden age’ of GPCR discovery is here

1

~400

GPCR targets
active indiseases2~34%

of FDAapprovals
target GPCRs1

27%
of global
sales
are GPCR
drugs1NEUROLOGICAL DISORDERS
GASTROINTESTINAL DISEASESIMMUNOLOGY/ONCOLOGYMETABOLIC DISORDERS
CARDIOVASCULARRESPIRATORYGPCRs are active in a wide range of disease areas,
and offer broad therapeutic potential

GPCR research has led to more than 700 approved drugs
over previous decades and is still ripe for development3

Sources: 1 “Unexplored opportunities in the druggable human genome”, Nature Reviews, 2016 ; 2 “Trends in GPCR in Drug Discovery – new agents, targets and indications”, Nature Reviews, 2017; 3 “Septerna
emerges with $100m to spark second golden age of prolific drug target GPCR with pioneer as co-founder” by Kyle LaHucik via Fierce Biotech, Jan 27 2022;

8

DISCOVERY PLATFORM

PARTNERSHIPS

TRANSFORMING R&D

ACTIVATING JAPANWorld-leaders choose our platform to prosecute complex GPCRs

1

Pre-Disc. / Discovery

Target ID

Preclinical studies

Structure

Clinical studies

Hit ID

Commercialization

Multi-target Discovery Collaborations

Lead Optimization

Total Potential
Milestones1$1.8bnCore
Technologies
Latest additions
to our platform

StaR®
(Stabilized Receptor)

SBDD(Structure-Based
Drug Design)

CryoEM

DEL Screening(DNA Encoded Library)++“for better compounds faster”

1Potential option fees, development, regulatory and commercial milestone payments at time of signing. Sosei Heptares is also eligible to receive tiered royalties ranging from high single digit to mid-teen
percentage on future net sales of any products developed under the partnerships

9$1.2bn$1.2bnProtein Binder Toolkit“for difficult targets faster”$1.0bn$730m

DISCOVERY PLATFORM

PARTNERSHIPS

TRANSFORMING R&D

ACTIVATING JAPANClinical stage partnerships (Muscarinic Programs)

2

Phase II initiated ‘22
Sosei Heptares received$100m upfront, +$30m @ Ph 2
Sosei Heptares to receive ongoing
R&D funding and up to $2.6bn
in potential development, regulatory
and commercial milestones,
plus tiered double digit percentage
royalties on net sales
Sosei Heptares retains rights todevelop all M1 agonists in Japan in
all indications, with NBIX receiving codevelopment and profit share options

Developing novel muscarinic receptor agonists for schizophrenia and other neuropsychiatric disorders
Source: Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2022 Financial Results
https://www.neurocrine.com/assets/2022/12/NBIX-Q3-2022-Earnings-Presentation-Final-10.31.22-1.pdf

10

DISCOVERY PLATFORM

PARTNERSHIPS

TRANSFORMING R&D

ACTIVATING JAPANClinical stage partnerships (Pfizer GLP-1 agonist for T2D and Obesity)

2

Phase II initiated ‘22

Well-positioned to compete on efficacy, tolerability and simplicity of administration vs. other oral therapies
Source: Pfizer Quarterly Corporate Performance – Second Quarter 2022 presentation
https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf

11

DISCOVERY PLATFORM

PARTNERSHIPS

TRANSFORMING R&D

Doing R&D differently to enhance productivity, value and success

3

TARGET
BIOLOGY• Entrench target biology to understanddisease processes• Define robust and testable hypothesis

TRANSLATIONALMEDICINE• Fully integrated preclinical and clinicalcapabilities• Lean, fit-for-purpose, and best practice

PROGRAMCENTRIC• Empowered and aligned program teams• Accountable for finance, risk, plannings• Functions exist to provide support

QUICK WIN /FAST FAIL• Shift program attrition to earlier,cheaper phase• Faster attrition drives reinvestment in
R&D “sweet spot”

Higher quality candidates, faster andmore cost-effectively
Larger late-stage partnering deals
in attractive areas of clear unmet need
Deeper in-house pipeline, and pathway forJapan clinical development

Complementing our world-leading science with operational best practice to increase efficiency, PoS, & ROI

12

ACTIVATING JAPANDISCOVERY PLATFORM

PARTNERSHIPS

TRANSFORMING R&D

ACTIVATING JAPANMultiple wholly-owned assets to begin clinical studies next 12 months

3

Indicationand target

TargetProduct
ProfileClinical starttarget13

Immunosuppression
in solid tumors

Schizophrenia
and Psychosis

Inflammatory
Bowel Disease

EP4 antagonist

GPR52 agonist

EP4 agonist• Once daily oral small molecule• To be used in combo withcheckpoint inhibitors• Collaboration with Cancer
Research UK

H1 2023• Once daily oral
small molecule• 24hr target engagement

H1 2023• Oral GI restricted• Good potency and selectivity• Minimal GI systemic exposure

H2 2023

DISCOVERY PLATFORM

PARTNERSHIPS

TRANSFORMING R&D

ACTIVATING JAPANHuge opportunity to create a disruptive pharma business in Japan

4

Secondlargestpharmamarket(excl.
China)

Large,
ageingpopulation

Universal
health caresystem

FOCUS: underserved,
specialty TA/DAs
ADOPT: lean, rational
development andcommercial model
BUILD: Japan aslynchpin market,
APAC for expansion

14

Stable, proinnovation
marketRelatively
weak
incumbents

Attractive
market for
disruptors

DISCOVERY PLATFORM

PARTNERSHIPS

TRANSFORMING R&D

Our plan for Japan

4

SEARCHDEVELOPBUILDEXECUTE

Target productopportunities
in selected
therapeutic areas

Mix ofin-licensing
and organic
development

Build scale
via virtual
R&D model

Expert team tonavigate clinical,
regulatory andcommercial

Over $500 million capital available to in-license approved
and/or post POC assets from pharma / biotech originators
15

ACTIVATING JAPANStrategy to enhance our success
Japan Commercial
Pharma Unit
Major milestone
generating
partnerships
Program-centric,
TM-led R&D
transformation
Potential stock
exchange
up-listing
Key initiatives over the next 3 years aimed at increasing corporate value

16

Our 2030 vision

Novel medicines on the market globally, through our collaborations with partners
Commercial business in Japan, based on in-licensed and in time, own products
Broad, deep and sustainable pipeline of programs with significant potential
Rapidly growing sales, cash flow and profits
Leading biotech in Japan driving innovative medicines to patients

17Appendix 1
Additional information

18

Board and Leadership team
Board of Directors

Executive Management

Senior R&D Leadership

Shinichi Tamura

Chris Cargill

Chris Cargill

Hironoshin Nomura

Dr. David Howe

Tomohiro Toyama

Dr. Matt Barnes

Dr. Marcus Messenger

Miwa Seki

Tadayoshi Yasui

Dr. Barry Kenny

Kieran Johnson

Dr. Stacey Southall

Kazuhiko Yoshizumi

Dr. Nigel Swain

Chairman of the Board

Representative Executive Officer,
President and CEO

External Independent Director

External Independent
Director

Kuniaki Kaga

External Independent
DirectorDr. David Roblin

External Independent Director

Representative Executive Officer,
President and CEO

Chief Financial Officer

President, Heptares Therapeutics,
Head of UK R&D

Representative Director President, Sosei Co.Ltd.

Chief Accounting Officer

Chief Compliance Officer

Dr. Alastair Brown

Senior Vice President, Translational Medicine

Vice President,
Non-CNS Development & Experimental Medicine

Vice President, Business Development

Senior Business Advisor

Senior Director, Biophysics

Senior Director, Medicinal Chemistry

Noriaki Nagai

Dr. Chris de Graaf

Rolf Soderstrom

Dr. Rie Suzuki

External Independent Director

External Independent Director

Senior Director, Computational Chemistry

Senior Director, Translational Medicine

Dr. Wendy Winchester

Senior Director, Translational Medicine

19Our unique and balanced business model continues to support asustainable financial profile
REVENUE (JPY million)

OPERATING PROFIT (JPY million)

17,712

8,904

10,00015,000

9,726

10,00011,408

8,842
3,505

0

2,872
2,532

FY18*

3,650

Upfront
Milestone

2,363

5,000

5,000

1,848

3,258

3,714

3,489

3,045

FY19

FY20

FY21

FY18*

Royality/Other(5,000)

2,904
928

FY19

FY20

3,775

OP
FY21

Core OP(4,444)(5,734)(10,000)

FY2021

CASH AT BANK (USD million)

386.5

522.1

140.3

FY19

20

0

2,189
384

Note: FY18 is 9 month from April 2018 to December 2018

FY20

FY21

•

~¥10bn new growth capital raised, adding funds earmarked toaccelerate our strategic growth initiatives and investments•

Net cash inflow of ¥20bn ($136m), resulting in a robust cash
balance of ¥60bn ($522m) at year end•

Capital to be deployed domestically in Japan to facilitate
in-licensing, acquisitions and co-investments

Partnered pipeline programs
CompoundTarget / Mechanism of Action

Modality

Indication

Seebri® Breezhaler®

LAMA

SME

COPD

Ultibro® Breezhaler®

LAMA+LABA

SME

COPD

Enerzair® Breezhaler®

LAMA+LABA+ICS

SME

AsthmaORAVI®

Antifungal agent miconazole

SME

Oropharyngeal candidiasis

NBI’568

Muscarinic M4 agonist

SME

Schizophrenia

Not disclosed

Muscarinic M1 agonist

SME

Neurology diseases

Not disclosed

Muscarinic M1/M4 agonist

SME

Neurology diseases

PF-07081532

GLP-1 agonist

SME

T2DM / ObesityPF-07054894

CCR6 antagonist

SME

Inflammatory bowel disease

PF-07258669

MC4 antagonist

SME

Anorexia

Not disclosed

CGRP antagonist

SME

Neurology diseases

Not disclosed

GPR35 agonist

SME

Inflammatory bowel diseaseNot disclosed

Multi target

SME/LME

Multiple indications

Not disclosed

Multi target

SME/LME

Gastrointestinal and otherNot disclosed

Multi target

SME

Inflammatory / Neurology

Not disclosed

Multi target

SME

Diabetes / MetabolicPartnerPartnered

Notes: SME = small molecule, LME = large molecule, mAb = monoclonal antibody. Seebri®, Ultibro®, Enerzair® and Breezhaler® are registered trademarks of Novartis AG.

21

Disc.

PreClin

Ph1

Ph2

Ph3

App

Mkt

Partnered pipeline programs (cont’d)CompoundTarget / Mechanism of Action

Modality

Indication

KY1051CXCR4 mAb

mAb

Immuno-oncology

Not disclosed

PAR-2

PeptideInflammatory diseases

Not disclosed

Targeted Protein Degradation

SME

Gastrointestinal disorders

Not disclosed

AI-Augmented Drug Discovery

SME

Neurology diseases

Not disclosed

Ion Channel Drug Discovery

SME

Neurology diseases

Not disclosed

Multi target AI-powered

SME/LME

Immune diseases

Not disclosed

Antibody Discovery

mAb

Disease-relevant GPCR targets

Not disclosed

Multi target AI-powered

SME/LME

Immune diseases

Not disclosed

Gut-brain axis drug discovery

SME

Gastrointestinal disorders

TMP301mGlu5 NAM

SME

Substance use disorders

Not disclosed

OX2 agonist (Oral)

SME

Narcolepsy

Co-development

Co-owned companies

Notes: SME = small molecule, LME = large molecule, mAb = monoclonal antibody

22

Partner

Disc.

PreClin

Ph1

Ph2

Ph3

App

Mkt

In-house pipeline programs
CompoundTarget / Mechanism

Modality

Indication

Not disclosed

H4 antagonist

SME

Atopic Dermatitis

HTL0039732

EP4 antagonist

SME

Immuno-oncology

Not disclosed

GPR52 agonist

SME

Neurology diseases

Not disclosed

EP4 agonist

SME

Inflammatory bowel diseaseNot disclosed

PAR-2 mAb

mAb

Atopic Dermatitis

Not disclosed

SARS CoV-2 Mpro

SME

Coronaviruses

Multiple programs

Not disclosed

SME/LME

Neurology diseases

Multiple programs

Not disclosed

SME/LMEGI and Inflammatory diseases

Multiple programs

Not disclosed

SME/LME

Immunology diseases

In-house Programs

In-house Programs (No longer internally funded. Targeting academic / industrial partnership)
HTL’310

SSTR5 agonist

PeptideHypoglycaemic disorders

HTL’097

GLP-1 antagonist

PeptideHypoglycaemic disorders

HTL’023

Dual GLP-2/GLP-1 agonist

PeptideIntestinal failure / NASH

Not disclosed

Apelin agonist

PeptidePulmonary Arterial Hypertension

Notes: SME = small molecule, LME = large molecule, mAb = monoclonal antibody

23

Originator

Disc.

PreClin

Ph1

Ph2

Ph3

App

Mkt

Appendix 2
Summary of wholly-owned
programs targeting FTIH in 2023
24

EP4 Antagonist

Background & Executive Summary
Target & Disease indication(s)• EP4 mediating PGE2 immunosuppression• Combination with checkpoint inhibitors (CPI’s) incancers with high expression of PGE2•

Proprietary StaR® technology used to identify highly potent and selective
antagonists of the EP4 receptor

Rationale•

Candidate is a class-matching, selective, potent, orally-bioavailable molecule;once daily, low dose, human administration is predicted to deliver target
suppression throughout dosing period•

Positive anti-tumour data in mouse syngeneic model of colorectal cancer(CT26) in combination with CPI•

Blockade of EP4 represents a promising therapeutic opportunity to remove
PGE2 mediated immunosuppression•

Working with CRUK to test compound in the clinic alone and in combination
with CPI’s which is expected to confer efficacy in previously CPI unresponsive
cancer patient populations• Tumour derived PGE2 induces profoundimmunosuppression in the tumour
microenvironment (TME), primarily acting via EP4• EP4 antagonism will relieve PGE2-mediatedimmunosuppression and switch the TME fromtumour tolerant to tumour aware. Phase 1 datawith competitor EP4 antagonist, E7046 supports
this hypothesis

Target Product/Molecule Profile• Once daily oral small molecule EP4 antagonist for
the treatment of PGE2 high cancers incombination with CPI’s

Current Status & Next Milestone• Preclinical studies and clinical manufacturecompleted• Clinical studies starting H1 2023

25

Executive Summary

EP4 Antagonist in Oncology – Proposed Mechanistic Hypotheses

26.

1.

Epithelial tumour cells secrete large quantities of PGE2 into
the TME.

2.

PGE2 increases proliferation of some tumours and thereby
increases their metastatic potential.

3.

PGE2 propagates an immunosuppressive TME; stimulates
MDSC differentiation, M2 polarisation and Treg migration.

4.

PGE2 propagates an immunosuppressive TME; reduces CD8
activity and killing, increases Th17 rather than Th1
differentiation, supports DC maturation towards atolerogenic state, decreases NK cell migration andactivation.

5.

Together these effects combine to make the patient tolerant
to their growing tumour.

6.

Multiple licensed pharmacological agents can reduce PGE2
generation through COX1/2 suppression. We hypothesisethat clinically relevant regimens of these agents fail toeffectively suppress TME PGE2.

7.

Reducing immunosuppression in the TME in combinations
with CPI’s will improve response rates in specific cancer
patient populations.
26

GPR52 Agonist

Background & Executive Summary
Target & Disease indication(s)• Oral small molecule GPR52 agonist• Schizophrenia• Psychosis and/or cognitive decline in dementias

Executive Summary•

Therapy to address positive symptoms, negative symptoms and cognitive
impairment in schizophrenia, without adverse effects typically associatedwith antipsychotics•

Potential for other patient settings (e.g. cognition and/or psychosis indementias)•

High quality molecule (HTL’149) in preclinical development• Excellent pharmacology and DMPK profile• In vivo activity in efficacy models• Rodent and dog MTD/DRFs completed;• Route/process development completed; GMP manufacture ongoing• FTIH start 2Q23•

Back-up molecules identified in other series•

Biomarker validation ongoing

Rationale• GS coupled Orphan GPCR
• Co-located with D2 receptors in medium spiny neurons(MSN) and with D1 in prefrontal cortex (PFC)• GPR52 activation will afford a D2 antagonist-like effect in
D2 MSNs and a D1 agonist like effect in PFC• i.e. an antipsychotic and pro-cognitive profile• Novel mechanism to treat both positive, negative andcognitive symptoms of schizophrenia

Target Product/Molecule Profile• Once daily oral small molecule

Current Status & Next Milestone• Candidate status• FTIH starting H1 2023

27

GPR52 Agonist Target Rationale

Treatment of positive symptoms and cognitive dysfunction in Schizophrenia
Striatopallidal neurons

Prefrontal cortical neurons

Rationale• GPR52 receptors principally co-located with D2 and D1
receptors• D2 in Medium Spiny Neurons• D1 in Prefrontal Cortex• GPR52 Activation  cAMP•
D2 Antagonist-like effect in Medium Spiny
Neurons Psychosis•
D1 Agonist-like effect in Prefrontal Cortex
 Cognition & negative symptoms

Proposed GPR52 signal transduction.
GPR52 activation counteracts Gi/o-coupled D2
receptors in striatopallidal neurons

Potentiates NMDA activity through phosphorylationof the NMDA receptor via cAMP/PKA, as seen in D1
receptor-NMDA signal transduction

Source: Novel Therapeutic GPCRs for Psychiatric Disorders: Komatsu, Int. J. Mol. Sci. 2015, 16, 14109; doi:10.3390/ijms160614109

28• No side effects associated with antipsychotics due toblockade of other D2 receptor populations• Potential for other indications / disease settings e.g.
psychosis / cognition in dementia)

GI restricted EP4 Agonist for the treatment of IBD
Background & Executive Summary
Target & Disease indication•

Inflammatory bowel disease (IBD)

Executive Summary•

Target Rationale• IBD genetic risk association• PGE2 has well documented mucosal
protective roles – key role in maintaining gut
homeostasis and promoting mucosal repair.
• Through combined anti-inflammatory andbarrier protecting effects, EP4 agonists are
expected to bring benefits in IBD andpromote mucosal healing

29•

Strong commercial opportunity for novel oral agents that can promote mucosal
healing to induce long term remission & reduce risk of surgery.

•

Current therapeutic strategies primarily target immune pathways: but only 20-40%
achieve long term remission with existing biologic therapies•

FIC opportunity for an oral gut restricted agent to promote regeneration and mucosal repair
via a differentiated MOA on the epithelial axis

Oral GI restricted EP4 agonist with goodpotency and selectivity. GI targetingstrategy with minimal systemic exposure.

Status: Candidate Nomination
Next Milestone: Candidate Selection

Strong mechanistic rationale in IBD supported by human genetic evidence.

Sosei Heptares is developing an oral GI restricted EP4 agonist molecule with minimal
systemic exposure for the treatment of IBD• Successful application of SBDD to design molecules with excellent GI restricted
properties• Lead molecule has completed candidate nomination package and is beingtransitioned to full preclinical development.
• High potent EP4 agonist with low oral bioavailability in preclinical species• Robust efficacy demonstrated in rodent colitis models.
• Good in vitro safety profile and early toxicology studies completed.

Current Status & next milestone
•
•

•

•

Target Molecule Profile•EP4 represents an attractive target for the treatment of IBD

Oral GI restricted EP4 agonist for the treatment of IBD
Proposed Mechanistic Hypotheses

Proposed benefits of
EP4 agonist
 Intestinal homeostasis – EP4
accelerates mucosal healing via
promoting regeneration and repairof damaged epithelial mucosa. EP4
agonists promote barrier function
via direct action on gut epithelial
cells.
 Immune cell function– EP4 isexpressed in gut immune cells andregulates Th1 cytokine release.
EP4 signalling promotes

Antiintegrins

differentiation of proresolving
macrophages.

Source: Adapted from (Weisshof et al 2018)

30.

Key:

Locations
SOSEI GROUPPMO Hanzomon 11F

Steinmetz Building

North West House

2-1 Kojimachi, Chiyoda-ku

Granta Park, Cambridge

119 Marylebone RoadTokyo 102-0083

CB21 6DG

London NW1 5PU

Japan

United Kingdom

United Kingdom